메뉴 건너뛰기




Volumn 25, Issue 3, 2011, Pages 139-146

Interpretation of cytogenetic and molecular results in patients treated for CML

Author keywords

Chronic myeloid leukemia; Cytogenetic response; Dasatinib; Imatinib; Molecular response; Nilotinib

Indexed keywords

DASATINIB; IMATINIB; INTERFERON; NILOTINIB;

EID: 79953218323     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2011.02.001     Document Type: Article
Times cited : (21)

References (40)
  • 1
    • 67651184109 scopus 로고    scopus 로고
    • Milestones and monitoring in patients with CML treated with imatinib
    • Deininger M.W. Milestones and monitoring in patients with CML treated with imatinib. Hematol Am Soc Hematol Educ Program 2008, 419-426.
    • (2008) Hematol Am Soc Hematol Educ Program , pp. 419-426
    • Deininger, M.W.1
  • 2
    • 0029947186 scopus 로고    scopus 로고
    • Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
    • Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal GM., Fanning S., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2:561-566.
    • (1996) Nat Med , vol.2 , pp. 561-566
    • Druker, B.J.1    Tamura, S.2    Buchdunger, E.3    Ohno, S.4    Segal, G.M.5    Fanning, S.6
  • 3
    • 61849163272 scopus 로고    scopus 로고
    • Molecular biology of bcr-abl1-positive chronic myeloid leukemia
    • Quintás-Cardama A., Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009, 113:1619-1630.
    • (2009) Blood , vol.113 , pp. 1619-1630
    • Quintás-Cardama, A.1    Cortes, J.2
  • 4
    • 73349122639 scopus 로고    scopus 로고
    • Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet
    • Baccarani M., Cortes J., Pane F., Niederwieser D., Saglio G., Apperley J., et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009, 27:6041-6051.
    • (2009) J Clin Oncol , vol.27 , pp. 6041-6051
    • Baccarani, M.1    Cortes, J.2    Pane, F.3    Niederwieser, D.4    Saglio, G.5    Apperley, J.6
  • 5
    • 10744233716 scopus 로고    scopus 로고
    • Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
    • O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994-1004.
    • (2003) N Engl J Med , vol.348 , pp. 994-1004
    • O'Brien, S.G.1    Guilhot, F.2    Larson, R.A.3    Gathmann, I.4    Baccarani, M.5    Cervantes, F.6
  • 6
    • 67349233062 scopus 로고    scopus 로고
    • Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
    • Hochhaus A., O'Brien S.G., Guilhot F., Druker BJ., Branford S., Foroni L., et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009, 23:1054-1061.
    • (2009) Leukemia , vol.23 , pp. 1054-1061
    • Hochhaus, A.1    O'Brien, S.G.2    Guilhot, F.3    Druker, B.J.4    Branford, S.5    Foroni, L.6
  • 8
    • 73849126019 scopus 로고    scopus 로고
    • State-of-the-art in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors: evolutionary trends in diagnosis, monitoring and treatment
    • Aguayo A., Couban S. State-of-the-art in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors: evolutionary trends in diagnosis, monitoring and treatment. Leuk Lymphoma 2009, 50(Suppl 2):1-8.
    • (2009) Leuk Lymphoma , vol.50 , Issue.SUPPL. 2 , pp. 1-8
    • Aguayo, A.1    Couban, S.2
  • 9
    • 55349096650 scopus 로고    scopus 로고
    • Chronic myeloid leukemia: molecular monitoring in clinical practice
    • Branford S. Chronic myeloid leukemia: molecular monitoring in clinical practice. Hematol Am Soc Hematol Educ Program 2007, 376-383.
    • (2007) Hematol Am Soc Hematol Educ Program , pp. 376-383
    • Branford, S.1
  • 10
    • 19244366937 scopus 로고    scopus 로고
    • Minimal residual disease in chronic myeloid leukemia
    • Löwenberg B. Minimal residual disease in chronic myeloid leukemia. N Engl J Med 2003, 349:1399-1401.
    • (2003) N Engl J Med , vol.349 , pp. 1399-1401
    • Löwenberg, B.1
  • 11
    • 14644441656 scopus 로고    scopus 로고
    • Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment
    • Tefferi A., Dewald G.W., Litzow M.L., Cortes J., Mauro MJ., Talpaz M., et al. Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment. Mayo Clin Proc 2005, 80:390-402.
    • (2005) Mayo Clin Proc , vol.80 , pp. 390-402
    • Tefferi, A.1    Dewald, G.W.2    Litzow, M.L.3    Cortes, J.4    Mauro, M.J.5    Talpaz, M.6
  • 12
    • 41349123259 scopus 로고    scopus 로고
    • Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods
    • Kantarjian H., Schiffer C., Jones D., Cortes J. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood 2008, 111:1774-1780.
    • (2008) Blood , vol.111 , pp. 1774-1780
    • Kantarjian, H.1    Schiffer, C.2    Jones, D.3    Cortes, J.4
  • 13
    • 70350717760 scopus 로고    scopus 로고
    • How I monitor residual disease in chronic myeloid leukemia
    • Radich J.P. How I monitor residual disease in chronic myeloid leukemia. Blood 2009, 114:3376-3381.
    • (2009) Blood , vol.114 , pp. 3376-3381
    • Radich, J.P.1
  • 14
    • 1842790087 scopus 로고    scopus 로고
    • A pathologist's perspective on bone marrow aspiration and biopsy: I. Performing a bone marrow examination
    • Riley R.S., Hogan T.F., Pavot D.R., Forsythe R., Massey D., Smith E., et al. A pathologist's perspective on bone marrow aspiration and biopsy: I. Performing a bone marrow examination. J Clin Lab Anal 2004, 18:70-90.
    • (2004) J Clin Lab Anal , vol.18 , pp. 70-90
    • Riley, R.S.1    Hogan, T.F.2    Pavot, D.R.3    Forsythe, R.4    Massey, D.5    Smith, E.6
  • 15
    • 3242723218 scopus 로고    scopus 로고
    • Cytogenetic and fluorescence in situ hybridization monitoring in Ph+chronic myeloid leukemia patients treated with imatinib mesylate
    • Fugazza G., Miglino M., Bruzzone R., Quintino S., Gatti AM., Grasso R., et al. Cytogenetic and fluorescence in situ hybridization monitoring in Ph+chronic myeloid leukemia patients treated with imatinib mesylate. J Exp Clin Cancer Res 2004, 23:295-299.
    • (2004) J Exp Clin Cancer Res , vol.23 , pp. 295-299
    • Fugazza, G.1    Miglino, M.2    Bruzzone, R.3    Quintino, S.4    Gatti, A.M.5    Grasso, R.6
  • 16
    • 0036752111 scopus 로고    scopus 로고
    • Correlation of three methods of measuring cytogenetic response in chronic myelocytic leukemia
    • Lesser M.L., Dewald G.W., Sison C.P., Silver R.T. Correlation of three methods of measuring cytogenetic response in chronic myelocytic leukemia. Cancer Genet Cytogenet 2002, 137:79-84.
    • (2002) Cancer Genet Cytogenet , vol.137 , pp. 79-84
    • Lesser, M.L.1    Dewald, G.W.2    Sison, C.P.3    Silver, R.T.4
  • 17
    • 0142182240 scopus 로고    scopus 로고
    • FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib
    • Reinhold U., Hennig E., Leiblein S., Niederwieser D., Deininger M.W. FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib. Leukemia 2003, 17:1925-1929.
    • (2003) Leukemia , vol.17 , pp. 1925-1929
    • Reinhold, U.1    Hennig, E.2    Leiblein, S.3    Niederwieser, D.4    Deininger, M.W.5
  • 18
    • 73949153481 scopus 로고    scopus 로고
    • Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP
    • Testoni N., Marzocchi G., Luatti S., Amabile M., Baldazzi C., Stacchini M., et al. Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. Blood 2009, 114:4939-4943.
    • (2009) Blood , vol.114 , pp. 4939-4943
    • Testoni, N.1    Marzocchi, G.2    Luatti, S.3    Amabile, M.4    Baldazzi, C.5    Stacchini, M.6
  • 19
    • 75749129911 scopus 로고    scopus 로고
    • Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia
    • Cortes J.E., Jones D., O'Brien S., Jabbour E., Ravandi F., Koller C., et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2010, 28:398-404.
    • (2010) J Clin Oncol , vol.28 , pp. 398-404
    • Cortes, J.E.1    Jones, D.2    O'Brien, S.3    Jabbour, E.4    Ravandi, F.5    Koller, C.6
  • 20
    • 45149087139 scopus 로고    scopus 로고
    • Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib
    • Hochhaus A., Baccarani M., Deininger M., Apperley JF., Lipton JH., Goldberg SL., et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008, 22:1200-1206.
    • (2008) Leukemia , vol.22 , pp. 1200-1206
    • Hochhaus, A.1    Baccarani, M.2    Deininger, M.3    Apperley, J.F.4    Lipton, J.H.5    Goldberg, S.L.6
  • 21
    • 77953725855 scopus 로고    scopus 로고
    • Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia
    • Kantarjian H., Shah N.P., Hochhaus A., Cortes J., Shah S., Ayala M., et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010, 362:2260-2270.
    • (2010) N Engl J Med , vol.362 , pp. 2260-2270
    • Kantarjian, H.1    Shah, N.P.2    Hochhaus, A.3    Cortes, J.4    Shah, S.5    Ayala, M.6
  • 22
    • 36348968931 scopus 로고    scopus 로고
    • Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
    • Kantarjian H.M., Giles F., Gattermann N., Bhalla K., Alimena G., Palandri F., et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007, 110:3540-3546.
    • (2007) Blood , vol.110 , pp. 3540-3546
    • Kantarjian, H.M.1    Giles, F.2    Gattermann, N.3    Bhalla, K.4    Alimena, G.5    Palandri, F.6
  • 24
    • 49249121723 scopus 로고    scopus 로고
    • Intermittent target inhibition with dasatinib 100mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia
    • Shah N.P., Kantarjian H.M., Kim D.W., Réa D., Dorlhiac-Llacer PE., Milone JH., et al. Intermittent target inhibition with dasatinib 100mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008, 26:3204-3212.
    • (2008) J Clin Oncol , vol.26 , pp. 3204-3212
    • Shah, N.P.1    Kantarjian, H.M.2    Kim, D.W.3    Réa, D.4    Dorlhiac-Llacer, P.E.5    Milone, J.H.6
  • 25
    • 54049139246 scopus 로고    scopus 로고
    • Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials
    • Branford S., Fletcher L., Cross N.C., Müller MC., Hochhaus A., Kim DW., et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008, 112:3330-3338.
    • (2008) Blood , vol.112 , pp. 3330-3338
    • Branford, S.1    Fletcher, L.2    Cross, N.C.3    Müller, M.C.4    Hochhaus, A.5    Kim, D.W.6
  • 26
    • 33745603988 scopus 로고    scopus 로고
    • Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
    • Hughes T., Deininger M., Hochhaus A., Branford S., Radich J., Kaeda J., et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006, 108:28-37.
    • (2006) Blood , vol.108 , pp. 28-37
    • Hughes, T.1    Deininger, M.2    Hochhaus, A.3    Branford, S.4    Radich, J.5    Kaeda, J.6
  • 27
    • 10744229080 scopus 로고    scopus 로고
    • Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
    • Hughes T.P., Kaeda J., Branford S., Rudzki Z., Hochhaus A., Hensley ML., et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003, 349:1423-1432.
    • (2003) N Engl J Med , vol.349 , pp. 1423-1432
    • Hughes, T.P.1    Kaeda, J.2    Branford, S.3    Rudzki, Z.4    Hochhaus, A.5    Hensley, M.L.6
  • 28
    • 77949767505 scopus 로고    scopus 로고
    • International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib
    • abstr 1126.
    • Deininger M., O'Brien S.G., Guilhot F., Goldman JM., Hochhaus A., Hughes TP., et al. International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. ASH Annu Meet Abstr 2009, 114. abstr 1126.
    • (2009) ASH Annu Meet Abstr , vol.114
    • Deininger, M.1    O'Brien, S.G.2    Guilhot, F.3    Goldman, J.M.4    Hochhaus, A.5    Hughes, T.P.6
  • 29
    • 49149111543 scopus 로고    scopus 로고
    • Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis
    • de Lavallade H., Apperley J.F., Khorashad J.S., Milojkovic D., Reid AG., Bua M., et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008, 26:3358-3363.
    • (2008) J Clin Oncol , vol.26 , pp. 3358-3363
    • de Lavallade, H.1    Apperley, J.F.2    Khorashad, J.S.3    Milojkovic, D.4    Reid, A.G.5    Bua, M.6
  • 30
    • 74549211342 scopus 로고    scopus 로고
    • Management of chronic myeloid leukaemia in clinical practice in France: results of the French subset of patients from the UNIC study
    • Michallet M., Tulliez M., Corm S., Gardembas M., Huguet F., Oukessou A., et al. Management of chronic myeloid leukaemia in clinical practice in France: results of the French subset of patients from the UNIC study. Curr Med Res Opin 2010, 26:307-317.
    • (2010) Curr Med Res Opin , vol.26 , pp. 307-317
    • Michallet, M.1    Tulliez, M.2    Corm, S.3    Gardembas, M.4    Huguet, F.5    Oukessou, A.6
  • 32
    • 20944442975 scopus 로고    scopus 로고
    • Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
    • Cortes J., Talpaz M., O'Brien S., Jones D., Luthra R., Shan J., et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005, 11:3425-3432.
    • (2005) Clin Cancer Res , vol.11 , pp. 3425-3432
    • Cortes, J.1    Talpaz, M.2    O'Brien, S.3    Jones, D.4    Luthra, R.5    Shan, J.6
  • 33
    • 33744798191 scopus 로고    scopus 로고
    • Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients
    • Iacobucci I., Saglio G., Rosti G., Testoni N., Pane F., Amabile M., et al. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res 2006, 12:3037-3042.
    • (2006) Clin Cancer Res , vol.12 , pp. 3037-3042
    • Iacobucci, I.1    Saglio, G.2    Rosti, G.3    Testoni, N.4    Pane, F.5    Amabile, M.6
  • 34
    • 58149396984 scopus 로고    scopus 로고
    • European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor
    • Marin D., Milojkovic D., Olavarria E., Khorashad JS., de Lavallade H., Reid AG., et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008, 112:4437-4444.
    • (2008) Blood , vol.112 , pp. 4437-4444
    • Marin, D.1    Milojkovic, D.2    Olavarria, E.3    Khorashad, J.S.4    de Lavallade, H.5    Reid, A.G.6
  • 35
    • 79953187670 scopus 로고    scopus 로고
    • Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving dasatinib 100mg once daily
    • abstr 6512.
    • Shah N.P., Cortes J.E., Schiffer C.A., le Coutre P., Bahceci E., Lambert A., et al. Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving dasatinib 100mg once daily. ASCO Annu Meet Abstr 2009, 28. abstr 6512.
    • (2009) ASCO Annu Meet Abstr , vol.28
    • Shah, N.P.1    Cortes, J.E.2    Schiffer, C.A.3    le Coutre, P.4    Bahceci, E.5    Lambert, A.6
  • 36
    • 21144451094 scopus 로고    scopus 로고
    • In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
    • O'Hare T., Walters D.K., Stoffregen E.P., Jia T., Manley PW., Mestan J., et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005, 65:4500-4505.
    • (2005) Cancer Res , vol.65 , pp. 4500-4505
    • O'Hare, T.1    Walters, D.K.2    Stoffregen, E.P.3    Jia, T.4    Manley, P.W.5    Mestan, J.6
  • 38
    • 72149115014 scopus 로고    scopus 로고
    • Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: longer follow-up results of a phase II study
    • abstr 7029.
    • Kantarjian H., Giles F., Bhalla K., Pinilla J., Larson RA., Gattermann N., et al. Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: longer follow-up results of a phase II study. ASCO Annu Meet Abstr 2009, 27. abstr 7029.
    • (2009) ASCO Annu Meet Abstr , vol.27
    • Kantarjian, H.1    Giles, F.2    Bhalla, K.3    Pinilla, J.4    Larson, R.A.5    Gattermann, N.6
  • 39
    • 76249090055 scopus 로고    scopus 로고
    • Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
    • Branford S., Melo J.V., Hughes T.P. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?. Blood 2009, 114:5426-5435.
    • (2009) Blood , vol.114 , pp. 5426-5435
    • Branford, S.1    Melo, J.V.2    Hughes, T.P.3
  • 40
    • 73949145209 scopus 로고    scopus 로고
    • Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia
    • Rosti G., Palandri F., Castagnetti F., Breccia M., Levato L., Gugliotta G., et al. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood 2009, 114:4933-4938.
    • (2009) Blood , vol.114 , pp. 4933-4938
    • Rosti, G.1    Palandri, F.2    Castagnetti, F.3    Breccia, M.4    Levato, L.5    Gugliotta, G.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.